Chlamydia trachomatis and Neisseria gonorrhoeae testing guidance recommends extragenital screening with locally validated nucleic acid amplification tests, with anatomical sites tested separately. Evidence supports multi-patient combined aliquot pooled sampling (PS) for population screening; evidence for within-patient PS is sparse. Within-patient PS could be more cost-effective for triple-site testing, but requires distinct clinical pathways and consideration over loss of information to guide risk assessments and treatment. We explored PS attitudes and practices amongst clinicians in England. A cross-sectional web-based survey was distributed to clinical leads of sexual health services throughout England in February 2016. Fifty-two (52/216, 23%) services responded. One service reported current within-patient PS and two were awaiting implementation. Of the 49 services not pooling, five were considering implementation. Concerns raised included the inability to distinguish infection site(s) (36/52, 69%), absence of national guidance (34/52, 65%) and reduced assay performance (18/52, 34%). Only 8/52 (15%) considered the current level of evidence sufficient to support PS, with 40/52 (77%) requesting further validation studies and 39/52 (77%) national guidance. PS was rarely used by respondents to this survey, although the response rate was low. The clinical challenges presented by PS need to be addressed through further development of the evidence base.
Introduction
Increasing pressure on National Health Service (NHS) and public health budgets necessitates evaluation of clinical practice to reduce costs without negatively impacting on patient care. Pooled sampling (PS) is a potential cost-saving measure that involves testing multiple specimens using a single assay with further individual specimen testing only occurring if the pooled sample tests positive. 1 The potential value of PS for Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) testing using nucleic acid amplification tests (NAATs) has been highlighted, 2 with two possible approaches: pooling specimens from multiple patients (multi-patient pooled sampling [MPPS] ) or pooling specimens from multiple anatomical sites from the same patient (within-patient pooled sampling [WPPS]) ( Figure 1 ).
Although extragenital testing with NAATs is common in routine UK clinical practice, British and international guidance suggest caution due to potential issues with test performance and lack of manufacturer and regulatory authorisation; they further recommend that anatomical sites should be sampled and tested separately. [2] [3] [4] [5] [6] Only a few studies have evaluated PS in the NAAT era, using varied CT/NG testing platforms and sample types, and most focus on MPPS. However, only one platform to date has a published validation study for the analysis of pooled urine samples. 7 NAAT performance using MPPS methodologies varies with pool size and site of infection 8 but similar data do not exist for WPPS methods.
9,10 Furthermore, prevalence thresholds at which PS can become cost-neutral or cost-saving require consideration of cohort heterogeneity, which can be difficult to assess. 1, 8 There is currently no British or European guidance on the use of PS for CT/NG testing. With an expanding PS evidence base, and currently unknown levels of PS implementation, we aimed to establish the prevalence of current and intended PS practice in sexual health services (SHSs) in England and investigated the barriers and facilitators to its adoption in routine clinical practice.
Methods
We designed and distributed a web-based survey to explore attitudes and practices relating to PS among sexual health clinicians in England (online Appendix 1). Survey questions were devised to include key aspects of the evidence base identified from an initial literature review. Participants were asked about advantages and disadvantages of expanding PS within clinical practice, including consideration of the quality of current evidence and clinical guidance. Participants were presented with answer grids containing lists of possible responses identified in the literature, with some options for clarifications in free text. The survey was piloted by the authors and genitourinary medicine clinical specialist trainees and revised following feedback.
A link to the survey was sent to the clinical leads of SHSs in England. Participants were identified in contact lists for surveillance reporting to Public Health England (PHE) 
Results
In total, 52/216 (23.3%) services returned complete responses to the survey. Seventeen incomplete and four duplicate responses were excluded from the analysis. Responses were received from all PHE regions apart from the East Midlands (Tables 1 and 2 ).
Current or considered use of PS
One service reported current WPPS and two were awaiting imminent implementation of PS. Of the 49 services not pooling, five were considering implementation. Services with PS experience, or plans to implement PS, were introducing PS to facilitate cost-saving (3/3) and to be innovative (3/3), with 2/3 introducing PS as part of clinical research assessing PS. The single service which had introduced WPPS found benefits of cost-saving and increased clinic capacity, but experienced challenges with patient acceptability and a lack of national PS guidance.
Prospective view of PS
Of the 49 services without current or imminent PS activity, 15 (31%) were expecting PS to become future standard practice in SHS. The key benefit of PS identified by services was the potential for costsaving (41/49, 84%), with a smaller proportion looking to increase clinic capacity (9/49, 18%). Opportunities for innovation (12/49, 25%) and clinical research (11/49, 22%) were also identified.
Barriers to the wider implementation of PS
All respondents, regardless of PS experience, were asked about the negative aspects and perceived barriers to wider PS implementation. Commonly reported barriers to the wider implementation of PS were: loss of infection site information (36/52, 69%), absence of national guidance (34/52, 65%), lack of supportive evidence (21/52, 40%) and reduced assay sensitivity/specificity (18/52, 35%).
Current PS evidence base
Only 8/52 (15%) respondents considered the existing evidence sufficient to support PS, with 40/52 (77%) requesting further validation studies, 39/52 (77%) 
Discussion
To our knowledge, this is the first survey to assess current practice and opinion on the utilisation of MPPS or WPPS for CT/NG NAATs within SHSs. We have established that the use of PS is uncommon but almost one-third of services responding to the survey expected PS to become standard practice, highlighting the need for a robust evidence base and national guidance. The key driver for PS introduction was the potential for cost-saving. The majority of respondents expressed concerns about the wider implementation of PS from clinical and laboratory standpoints, underpinned by a lack of supportive evidence. Despite concerted efforts to engage SHS, the response rate was low, which influences the representativeness of the findings. Clinicians may have been more likely to respond if they had an interest in PS or were considering introducing it. Conversely, others may have opted not to respond if they felt they had insufficient knowledge to answer accurately. Our study may therefore overestimate the proportion anticipating PS to become standard practice. However, survey responses were from geographically-diverse locations across England. The survey content was informed by 12 although modelling suggests that savings may be more limited with increasing prevalence of Chlamydia and inhibitors of PCR. 13 Whilst financial considerations are important, this should not be at the detriment of the patient experience and outcomes, nor public health. No qualitative data are available regarding patients' opinions on WPPS, and the single site who had implemented PS in our survey found that challenges with patient acceptability were encountered. Sultan et al. reported that there was a high level of patient acceptability of the PS method used in their study. 10 Future work to explore the PS patient experience may be helpful.
Consideration must be given to re-sampling individual anatomical sites in patients testing positive from WPPS to ensure the identification of extragenital infections. Whilst not influencing treatment choice directly according to current clinical guidance, re-sampling provides insight into sexually transmitted infection (STI) transmission dynamics. Knowledge of specific infection sites informs not only individual risk reduction advice but collectively informs public health surveillance data around risk behaviours associated with STI acquisition and site-specific antimicrobial resistance profiles. 14 Treatment choice for any positive CT result which included a rectal sample should also ensure adequate therapy with doxycycline. 3 With widespread antimicrobial resistance amongst NG populations, it is important to ensure that PS does not hinder NG culture or test of cure pathways.
Within our survey, clinicians expressed concerns about a potential decrease in NAAT performance using PS. Caution with regard to the sensitivity/ specificity of NAATs for WPPS seems appropriate with existing studies showing mixed results: one study found a superior sensitivity of WPPS for identifying CT infection than vulvovaginal sampling alone, 9 whilst others have demonstrated inferior sensitivity amongst triple-site samples in men-who-have-sexwith-men. 10, 15 The potential effect of inhibitors on PS validity is also of some concern. There are no studies reviewing the effect of inhibitors on WPPS methods, and studies on MPPS have conflicting findings. 11, 16 These concerns could eventually be mitigated by developing PS methods and ensuring rigorous local laboratory validation. PS requires new laboratory processes for combining NAAT samples prior to assay testing, which need to consider handling, mixing and potential With the vast majority of clinicians feeling the current evidence base insufficient to confidently support PS, it is clear that significant unanswered questions remain. SHSs considering implementation of MPPS are likely to find an existing example of practice to base service change upon. WPPS is not a widely validated technique on many current commercial NAAT platforms. The practical implementation of any new sampling methodology is likely to generate challenges and we would welcome more data on services' experience with PS implementation. Further data assessing WPPS assay performance and cost-effectiveness are required.
The current financial pressures within SHSs in England are encouraging services to innovate to maintain standards of care with increasingly smaller budgets. We found that pooling of samples was uncommon among survey respondents. However, several services were considering implementing pooling and the majority of respondents saw potential cost savings of pooling as a positive feature. Considered debate regarding the level of influence that cost should have on clinical care is warranted, and with PS should recognise that with infinite resources separate-site NAAT testing would remain the gold standard. Further evidence and guidance from professional bodies would be helpful for clinicians and service commissioners.
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